Bluestar Launches PFAS-Free Silicone for Medical Devices
Device manufacturers can now use this silicone rubber to meet sustainability goals for patient-contact products.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Should companies be required to prioritize sustainable materials in medical device manufacturing?
Bluestar Silicones has introduced Silbione LSR 4755 PF, a PFAS-free liquid silicone rubber engineered specifically for medical device manufacturing. The new material supports healthcare applications requiring patient contact for up to 30 days while aiming to help producers meet evolving sustainability and regulatory standards.
Why it matters
The introduction of PFAS-free materials addresses growing regulatory pressures and corporate sustainability mandates facing medical device manufacturers. By shifting to compliant elastomers, operators can proactively align their supply chains with stricter material safety requirements.
The new elastomer is certified for patient contact lasting up to 30 days, serving as a substitute for traditional materials in healthcare settings. It is designed to meet ISO 10993 requirements for medical device components.
The players
Bluestar Silicones
An international manufacturer specializing in silicone materials for industrial and medical applications.
The details
Silbione LSR 4755 PF utilizes integrated lubricating technology to provide a non-stick surface, which can streamline assembly processes for medical device components. Additionally, the material incorporates delayed oil bleed technology specifically designed to reduce mold fouling during manufacturing, potentially improving throughput by minimizing the need for frequent cleaning cycles.
Timeline
October 22, 2026: Bluestar Silicones launched Silbione LSR 4755 PF.
Market Landscape
This launch aligns with the industry-wide transition toward materials compliant with ISO 10993 standards for medical device safety. It mirrors broader efforts to phase out PFAS in manufacturing while maintaining rigorous performance benchmarks for long-term patient contact.
Device manufacturers should evaluate their current inventory for PFAS content to determine if transitioning to this new material will simplify their regulatory compliance path. Operations managers should monitor whether the delayed oil bleed technology effectively reduces downtime in their specific injection molding workflows.
The takeaway
Operators should track the adoption of PFAS-free elastomers as a signal of shifting supply chain standards in the medical device sector. Ensure your procurement team audits current silicone components for PFAS classification to prepare for potential future regulatory mandates.
Further reading
Explore industry trends regarding material compliance and innovation in our Healthcare section.
Source note: This article includes information reported by Rubber Journal Asia -News on Rubber machinery , Manufacturers , Rubber chemical producers and Rubber processors.
Live Poll
Should companies be required to prioritize sustainable materials in medical device manufacturing?
